This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma
J Natl Compr Canc Netw. 2019 May;17(5.5) :615-617
PMID: 31117032 URL: https://www.ncbi.nlm.nih.gov/pubmed/31117032
AbstractAccording to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations.
NotesOlszanski, Anthony J. NCCN Annual Conference on Improving the Quality, Effectiveness, and Efficiency of Cancer Care Mar 21-22, 2019 Orlando, FL Nccn 1540-1413 J Natl Compr Canc Netw. 2019 May 1;17(5.5):615-617. doi: 10.6004/jnccn.2019.5019.